31 Mar 2022
Assets68.58
Total Income92.67
Profit After Tax3.13
NET Worth12.09
Reserves and Surplus11.69
Total Borrowing18.81
At a glance
Updated 2026-09-15The shares listed at ₹110.00, a 39.24% move from the issue price. Zenith Drugs is a SME IPO with an issue size of ₹40.68 crore, proposed for listing on NSE SME. The offer opens on 19th Feb 2024 and closes on 22nd Feb 2024. The issue structure includes a fresh issue of ₹33.94 crore. The current listing schedule points to 27th Feb 2024.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹40.68 Cr
Fresh issue₹33.94 Cr
Face value₹10
Price band₹75.00–₹79.00
Allotment23rd Feb 2024
Listing27th Feb 2024
Listing performance
Full performance ↗Issue price₹79.00
Listing price₹110.00
Current price—
Listing gain39.24%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹35.00
GMP / upper price44.30%
Est. listing₹114.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens19th Feb 2024
Closes22nd Feb 2024
Allotment23rd Feb 2024
Refund26th Feb 2024
Demat26th Feb 2024
Listing27th Feb 2024
Subscription demand
Full bidding ↗Total179.18×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 1600 | ₹126,400 |
Company
Incorporated2000
Use of proceeds
| Object | Amount |
|---|---|
| Purchase of Machinery & Equipments for Setting up New Unit | ₹10.61 Cr |
| Existing Manufacturing Block Upgradation | ₹2.11 Cr |
| Working Capital Requirements | ₹14.40 Cr |
| General Corporate Purposes | ₹8.84 Cr |
| Total | ₹35.96 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue69.48₹ Cr · -39.9% vs prior year
PAT5.39₹ Cr · +4.7% vs prior year
Assets112.49₹ Cr · +14.9% vs prior year
Net Worth22.65₹ Cr · +31.4% vs prior year
Borrowing29.03₹ Cr · +11.4% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2023
Assets97.94
Total Income115.70
Profit After Tax5.15
NET Worth17.24
Reserves and Surplus16.84
Total Borrowing26.05
30 Sep 2023
Assets112.49
Total Income69.48
Profit After Tax5.39
NET Worth22.65
Reserves and Surplus10.65
Total Borrowing29.03
KPIs
| KPI |
|---|
| ROE |
| ROCE |
| Debt / Equity |
| RoNW |
| PAT Margin |
| Price to Book Value |
Valuation & shareholding
Pre-IPO EPS4.29
Post-IPO EPS6.29
Pre-IPO P/E18.4
Post-IPO P/E12.56
Promoter holding pre100%
Promoter holding post69.98%
Market cap₹135.48 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Zenith Drugs IPO | — | 12.56 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Payment to the Lead Manager | ₹1.30 Cr |
| Underwriting Fees | ₹1.03 Cr |
| Market Making Fees | ₹2.14 Cr |
| Fees payable to Registrar to Issue | ₹0.03 Cr |
| Fees to Legal Advisor | ₹0.02 Cr |
| Advertisement Expenses | ₹0.05 Cr |
| Fees payable to Regulators including Stock Exchange & Depositories | ₹0.08 Cr |
| Printing & Distribution Expenses | ₹0.01 Cr |
| Marketing & Selling Expenses | ₹0.03 Cr |
| Payment to Sponsor Bank | ₹0.02 Cr |
| Statutory & Other Reports | ₹0.02 Cr |
Registrar & lead managers
Registrar
Bigshare Services Pvt.Ltd.Lead managers
- Gretex Corporate Services Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-15.
IPO UPDATE ALERTS
Register for IPO Updates →Track Zenith Drugs without missing an update
Register for subscription, GMP, allotment and listing notifications.